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Abstract:  Three different approaches were employed to assess various markers associated with sex differences in   
responses to methamphetamine (MA). Bioassay measures reveal that MA treatment results in significantly greater reduc-
tions in body weight and increases in body temperature in male mice. Protein and mRNA determinations show significant 
increases in Bcl-2 and PAI-1 in male mice, while females show significant increases in GFAP and decreases in IGF-1R 
following treatment with MA. In mice with a heterozygous mutation of their dopamine transporter (+/- DAT), only female 
mice show significant differences in dopamine transporter binding and mRNA and associated reductions in striatal   
dopamine content along with increases in MA-evoked striatal dopamine output. The identification of these sex-dependent 
differences in markers provides a foundation for more exhaustive evaluation of their impact upon, and treatment of,  
disorders/neurotoxicity of the nigrostriatal dopaminergic system and the bases for the differences that exist between   
females and males. 
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INTRODUCTION 
  Methamphetamine (MA) produces an acute increase in 
striatal dopamine (DA) output [1] and a long-lasting deple-
tion of striatal DA concentration, which is greater in male 
mice [2, 3]. Analogous gender differences exist in the clini-
cal literature. Women show lower amphetamine-evoked DA 
responses [4] and MA-induced toxicity is less pronounced in 
women [5]. Accordingly, significant sex differences exist 
with regard to uses of, and responses to, MA [6]. In this   
report we review our data on various parameters and signals  
as related with sex differences in MA-induced neurotoxicity 
upon striatal DA. 
Part 1: Bioassays  
  There are two biological measures that reveal sex differ-
ences as associated with MA-induced neurotoxicity – body 
weights and temperature. When comparing changes in body 
weight from the immediate pre-MA treatment level with that 
at 3-5 days post-MA treatment, there is a statistically signifi-
cant, approximately 1.0 gm greater reduction in body 
weights of male mice (Fig. 1B) as associated with increased 
striatal DA depletions (Fig. 1A). 
  There exists a fairly extensive literature base on the vari-
able of temperature and effects of MA [7]. We reported that 
estrogen treatment, which significantly diminishes MA-   
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induced neurotoxicity in female, but not male, mice, signifi-
cantly reduces body temperature only in female mice [8]. In 
response to MA (40 mg/kg), both females and males show 
increases in body temperature, however, this increase was 
significantly greater in males (Fig. 1C). Taken together these 
two bioassays reveal that in male mice, where an increased 
amount of striatal DA depletion is present to MA, there   
are corresponding increases in body weight reductions and 
increases in body temperature. 
Part 2: Protein and mRNA Levels 
Glial Fibrillary Acidic Protein (GFAP) 
  There exist some particularly intriguing changes in reac-
tive astrocytes as measured by GFAP between MA-treated 
female and male mice. Although basal levels of GFAP are 
greater in males [7], striatal GFAP mRNA was approxi-
mately two-fold greater in females (p = 0.06) at 7-days after 
MA (4 X 20 mg/kg @ 2 h intervals) (Fig. 2A) [2]. In these 
same mice, striatal DA, while severely depleted to approxi-
mately 20% of control values, remained significantly greater 
in females. These results were somewhat unexpected, but 
very similar to that reported for female and male mice 
treated with d-MDMA. With this treatment, male mice 
showed a more severe depletion of striatal DA (~ 10% of 
controls) accompanied by an approximately 2.7-fold increase 
in GFAP protein, while females showed a less severe DA 
depletion (~ 30% of controls) accompanied by an approxi-
mately 5.8-fold increase in GFAP protein [7]. When this 
information on the sex differences in striatal DA and GFAP 
is collated a significant relative sex differential in GFAP is  
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present in response to MA; that is, the approximately two-
fold greater levels of GFAP that are observed in males under 
basal conditions become approximately two-fold lower in 
males following MA treatment. The enhanced GFAP re-
sponse that we captured in females at this time point post-
MA may reveal a manner of restorative activity in astrocytes 
to prevent further decline in such functions as blood brain 
barrier disruption or demyelination of the nervous system. 
Plasminogen Activator Inhibitor-1 (PAI-1) 
  At 7 days post-MA, when striatal DA concentrations of 
female mice were significantly greater than males, an ap-
proximately 1.85-fold and statistically significant increase in 
PAI-1 was obtained in male mice, with no change in females 
(Fig. 2B) [2]. In general, basal levels of PAI-1 are greater in 
males [9] and men seem more responsive or sensitive to 
PAI-1 relationships [10]. Repeated MA administration pro-
duced significant, dose-dependent increases in tissue plasmi-
nogen activator mRNA in both the nucleus accumbens and 
striatum of mice [11]. Our findings appear relatively congru-
ent with that reported by others in that PAI-1 is more preva-
lent in males and, in turn, males seem more sensitive with 
regard to PAI-1 responses of stress or insult. The increased 
PAI-1 response in males may represent a PAI-1 activation by 
TGF-ß protein in the context of MA-evoked glutamate to 
result in the enhanced neurotoxicity and/or reflect an ongo-
ing inflammatory response as associated with the increased 
neurotoxicity of males. 
Bcl-2 
  When sex differences were evaluated for Bcl-2 in re-
sponse to MA, we found that striatal levels were signifi-
cantly increased in male, but not female, mice at 7 days post-
treatment with 40 mg/kg of MA (Fig. 2C). Striatal Bcl-
2/BAX ratios were significantly greater in wild type control 
(parkin) females, which appeared to be due mostly to lower 
BAX levels in females [12]. The increase in Bcl-2 we ob-
served in male mice at 7 days post-MA differs from de-
creases typically seen at much earlier time points post-MA. 
Male mice treated with MA (4 X 10 mg/kg @ 2h intervals) 
showed a significant down regulation in striatal Bcl-2 ex-
pression when sampled at 72 h post-MA [13]; and in immor-
talized striatal cell cultures, Bcl-2 was significantly de-
creased at 24 h post-treatment with 2 mM MA [14]. Since 
increased expression of Bcl-2 decreased the temporal- and 
dose-dependent loss of cell viability from immortalized cells 
exposed to MA [15], it was somewhat surprising to see these 
levels increased in males, where augmented neurotoxicity is 
present. The timing of Bcl-2 determinations might represent 
an important factor with regard to levels obtained and the 
elevated levels of Bcl-2, along with PAI-1, may indicate a 
need for a stronger recovery or compensatory response to 
MA in the male. 
Insulin-Like Growth Factor-1 Receptor (IGF-1R). 
  Administration of MA at either 20 or 40 mg/kg signifi-
cantly decreased striatal IGF-1R levels in female, but not 
male mice, as determined at 7-days post-MA treatment   
(Fig.  2D). The enhanced sensitivity in females may be of 
particular significance where a coactivation of estrogen and 
IGF-1 receptors seem to be involved with neuroprotection. 
Moreover, the capacity for IGF-1 to synergize with estrogen 
for activation of the mitogen-activated protein kinase (MAPK) 
and phosphoinositide 3-kinase (PI3K)/Akt pathways represent 
critical signal transduction casacades for neuroprotective 
actions [16].  
pAkt and GSK 3 ß 
  These two markers showed an overall, predominant MA-
effect. In both females and males these markers were de-
creased following MA treatment, with the degree of decrease 
being slightly greater in males. In the case of pAkt, this re-
duction achieved statistical significance (30% decrease). 
Such a reduction in pAkt might reflect a diminished activa-
tion of survival pathways due to the increased capacity for 
MA to decrease striatal DA and GFAP astrocyte expression 
in males. A number of markers indicated neither a sex differ-
ence nor effect of MA (Activin-like kinase 5, Akt, BAD, 
ERK 1 and 2, pERK 1 and 2, Fibronectin, pGSK 3ß, TGFß 
and TGFß R2).  
 
 
 
 
 
 
 
 
 
Fig. (1). Relationships (Mean and SEM) among methamphetamine (MA – 40 mg/kg)-induced striatal dopamine depletions (A - pg/mg), body 
weights (B - gm) and body temperatures (C - °C) in female and male mice. 42    Current Neuropharmacology, 2011, Vol. 9, No. 1  Dluzen et al. 
Part 3: +/- Dopamine Transporter KO Model 
  Given that a primary site for MA’s action is upon the 
dopamine transporter (DAT) and females show greater DAT 
function [17] and densities of DATs as reported in both labo-
ratory [18] and clinical [19] studies, we evaluated sex differ-
ences in dopaminergic function in mice with a DAT muta-
tion. A consistent finding resulting from comparisons of het-
erozygous mutant DAT (+/- DAT) mice is that this mutation 
does not exert equivalent effects upon the dopaminergic sys-
tem of females and males. Significant reductions are consis-
tently seen in +/- DAT female, but not male, mice for striatal 
DAT binding and substantia nigra binding and mRNA (Fig. 
3) [20]. As a result, in +/- DAT female, but not male, mice 
striatal DA concentrations and MA-evoked dopamine re-
sponses are altered [21]. While MA-evoked DA responses 
are greater in wild type males, this profile was reversed when 
tested in +/- DAT mice (Fig. 4). It seems as though males are 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Summary of changes (percents) in markers as determined from striatal tissue of methamphetamine-treated female and male mice. A. 
GFAP mRNA in males is approximately two-fold greater than females, but following methamphetamine treatment, GFAP levels are   
approximately 50% that of females. Levels for both PAI-1 (B) and Bcl-2 (C) were significantly increased in males. Levels of IGF-1R (D) 
were significant decreased in females. Data derived from references # [2, 7, 16]. 
 
 
 
 
 
 
 
 
 
Fig. (3). Dopamine Transporter (DAT) specific binding (Mean and SEM in fmol/mg of tissue) within the medial region of the anterior stria-
tum (A), substantia nigra (B) and DAT mRNA (relative optical density) within the substantia nigra (C) of +/+ DAT control and heterozygous 
mutant (+/- DAT) female and male mice. Levels from +/+ DAT females were significantly greater than all other conditions tested and only 
+/- DAT females showed significant decreases in DAT binding and mRNA. Data derived from reference # [20]. Markers Associated With Sex Differences In Methamphetamine-Induced  Current Neuropharmacology, 2011, Vol. 9, No. 1    43 
capable of generating compensatory responses which enables 
them to maintain their dopaminergic responses in the pres-
ence of a DAT allele deletion. These findings have important 
implications as changes in the DAT that can occur with age 
or in conditions like MA abuse or Parkinson’s disease may 
have decidedly different consequences for females and 
males. 
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